CCM
PTCT icon

Camber Capital Management’s PTC Therapeutics PTCT Stock Holding History

Camber Capital Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,500,000
Closed -$76.4M – 32
2025
Q1 		$76.4M Sell
1,500,000
-1,700,000
-53% -$84.8M 2.72% 9
2024
Q4 		$144M Sell
3,200,000
-300,000
-9% -$12.8M 3.34% 7
2024
Q3 		$130M Hold
3,500,000
– – 4.12% 7
2024
Q2 		$107M Sell
3,500,000
-500,000
-13% -$16.2M 2.96% 11
2024
Q1 		$116M Hold
4,000,000
– – 2.85% 12
2023
Q4 		$110M Buy
4,000,000
+600,000
+18% +$13.7M 2.81% 12
2023
Q3 		$76.2M Buy
3,400,000
+900,000
+36% +$33.5M 2.51% 17
2023
Q2 		$102M Hold
2,500,000
– – 3.31% 12
2023
Q1 		$121M Sell
2,500,000
-250,000
-9% -$11.4M 3.72% 12
2022
Q4 		$105M Buy
2,750,000
+300,000
+12% +$12.5M 3.6% 10
2022
Q3 		$123M Hold
2,450,000
– – 3.77% 9
2022
Q2 		$98.1M Buy
2,450,000
+700,000
+40% +$24.5M 4.26% 9
2022
Q1 		$65.3M Buy
1,750,000
+1,000,000
+133% +$38.5M 2.36% 17
2021
Q4 		$29.9M Hold
750,000
– – 1.03% 28
2021
Q3 		$27.9M Buy
+750,000
New +$30.8M 0.86% 31
2017
Q3 		– Sell
-500,000
Closed -$9.16M – 26
2017
Q2 		$9.16M Sell
500,000
-750,000
-60% -$10.1M 0.45% 30
2017
Q1 		$12.3M Buy
+1,250,000
New +$15.1M 0.5% 27
2016
Q4 		– Sell
-2,000,000
Closed -$28M – 40
2016
Q3 		$28M Buy
2,000,000
+500,000
+33% +$4.06M 1.23% 24
2016
Q2 		$10.5M Buy
1,500,000
+606,100
+68% +$4.45M 0.51% 36
2016
Q1 		$5.76M Buy
893,900
+393,900
+79% +$6.84M 0.34% 40
2015
Q4 		$16.2M Buy
+500,000
New +$14.7M 1.05% 27
2015
Q1 		– Sell
-525,000
Closed -$27.2M – 42
2014
Q4 		$27.2M Buy
525,000
+366,851
+232% +$16.1M 1.81% 25
2014
Q3 		$6.96M Buy
+158,149
New +$4.95M 0.65% 31

Other funds holding PTCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Camber Capital Management's PTCT Position: Q2 2025 in Review

Camber Capital Management sold out of PTC Therapeutics (PTCT) in Q2 2025, closing a stake of 1,500,000 shares — an estimated $76.4M sold.

Camber Capital Management first reported a position in PTCT in Q3 2014 and held it in 23 quarters. The position peaked at $144M in Q4 2024. 283 funds tracked by Wall St. Rank hold PTCT as of Q2 2025.

  • Camber Capital Management reported no remaining PTC Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Camber Capital Management sold 1,500,000 PTC Therapeutics shares in Q2 2025, an estimated $76.4M.
  • Camber Capital Management first reported a position in PTC Therapeutics in Q3 2014 and held it in 23 quarters.
  • Camber Capital Management's PTC Therapeutics position peaked at $144M in Q4 2024.
  • 283 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2025.

Based on Camber Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.